Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase 1 2Phase 1/2 1

Status

Withdrawn 2Terminated 2Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5Gynecologic 4Breast 2NET 1Endocrine 1

Conditions

Glioblastoma 2Meningioma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Temozolomide 258Radiotherapy 147Bevacizumab 142Etoposide 68Cyclophosphamide 68Carboplatin 66Magnetic Resonance Spectroscopy 58Irinotecan 53Cisplatin 52Vincristine 45Filgrastim 43pembrolizumab 40Radiosurgery 36Nivolumab 36Radiation 34Topotecan 31Doxorubicin 30Specimen Handling 29sargramostim 28Lomustine 27Erlotinib Hydrochloride 27Peripheral Blood Stem Cell Transplantation 25Carmustine 25Thiotepa 24Everolimus 23Chemotherapy, Adjuvant 23Surgical Procedures, Operative 22Isotretinoin 22Ipilimumab 22Melphalan 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × TIC10 compound × CNS × Clear all
NCT06012929 2026-01-26

A Study of ONC201 for Refractory Meningioma

University of Nebraska

Phase 2 Withdrawn
CNS

Meningioma

NCT05009992 2025-12-17

PNOC022

University of California, San Francisco

Phase 2 Recruiting
360 enrolled
CNS

Diffuse Intrinsic Pontine Glioma

NCT03295396 2025-07-28

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Jazz Pharmaceuticals

Phase 2 Terminated
73 enrolled 13 charts 1 FDA
CNS

Glioma

NCT02525692 2024-12-24

Oral ONC201 in Adult Recurrent Glioblastoma

Jazz Pharmaceuticals

Phase 2 Terminated
84 enrolled 14 charts 1 FDA
CNS

Glioblastoma

NCT04629209 2023-11-24

A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma

Masonic Cancer Center, University of Minnesota

Phase 2 Withdrawn
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡